Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

Amphetamine-Related Disorders Clinical Trial

Official title:

Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00033072
• Other study ID #: NIDA-CTO-0004-1
• Status: Active, not recruiting
• Phase: Phase 1
• First received: April 5, 2002
• Last updated: January 10, 2017
• Start date: September 2001
• Est. completion date: October 2002

Study information

• Verified date: November 2003
• Source: National Institute on Drug Abuse (NIDA)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Description:

To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.

Other known NCT identifiers

• NCT00024882

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 16
• Est. completion date: October 2002
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals

• Be able to verbalize understanding of consent form; provide written informed consent

Exclusion Criteria:

• Please contact site for more information

Study Design

Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Amphetamine-Related Disorders

Intervention

Drug:
• Selegiline

Locations

Country	Name	City	State
United States	UCLA Integrated Substance Abuse Program	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	safety of selegiline
Primary	pharmacokinetic assessment